Vectura Group today announces signing an agreement with Hikma Pharmaceuticals for the global development and commercialisation of generic versions of GSK’s Ellipta® portfolio, utilising Vectura’s proprietary Open-Inhale-Close dry powder inhaler device.
Following interactions with US FDA, the Open-Inhale-Close dry powder inhaler device has the potential to be developed as an AB-rated substitutable drug-device combination for generic versions of the GSK Ellipta® portfolio. This presents a significant opportunity, with net sales for Ellipta® products in the US projected to be $4bn* by 2024 and over $5.5bn* globally.
(*Source: Global Data October 2018).
James Ward-Lilley, Chief Executive Officer of Vectura, said: “This is a highly significant and valuable agreement for Vectura, reflecting our increased focus in our complex inhaled generic portfolio. The agreement validates Vectura’s rare, industry-leading development capabilities. It also reflects the strong existing relationship we have with Hikma and their confidence in the future of the substitutable inhaled generic segment including VR315 our joint Advair® generic programme.”
Briefing for Analysts
James was joined by Roger Heerman, Executive Vice President Business Development, and Martin Oliver, Senior Vice President Generic Programmes, for a live conference call to discuss the agreement. A copy of the presentation and a recording of the call is now available here.